Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Host: Joshua E. Reuss, MD
\n\n\n \n
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.